Safety of consecutive same-day bilateral intravitreal dexamethasone implant (ozurdex)

Conclusion: Consecutive same-day bilateral intravitreal dexamethasone (Ozurdex) is safe and well tolerated. There were no significant complications, and patients preferred continuing bilateral implantation after their initial trial. Same-day treatment may optimize efficiency and decrease patient visits and ultimate treatment burden without compromising patient safety or clinical efficacy.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research